What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Antibody
- Cancer
Jean-Claude Bystryn mainly focuses on Immunology, Antibody, Vitiligo, Pemphigus and Antigen.
Immunology connects with themes related to Melanoma in his study.
The various areas that Jean-Claude Bystryn examines in his Antibody study include Internal medicine and Immunopathology.
His work deals with themes such as Cell, Pigmentation disorder and Melanocyte, which intersect with Vitiligo.
He has included themes like Plasmapheresis, Acantholysis, Cyclophosphamide and Pemphigus vulgaris in his Pemphigus study.
His Antigen study integrates concerns from other disciplines, such as Pathogenesis, Immunoprecipitation, Hair follicle, Alopecia areata and Immunofluorescence.
His most cited work include:
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus (340 citations)
- The Adjuvant Therapy of Pemphigus: An Update (232 citations)
- Prognostic significance of hypopigmentation in malignant melanoma. (188 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Immunology, Antibody, Antigen, Melanoma and Pathology.
He combines subjects such as Pemphigus and Immunopathology with his study of Antibody.
His Antigen research is multidisciplinary, incorporating elements of Molecular biology, Cell, Epidermis and Immunoprecipitation.
His work in Melanoma tackles topics such as Melanoma Vaccine which are related to areas like Vaccination.
His study explores the link between Pathology and topics such as Guinea pig that cross with problems in Esophagus and Indirect immunofluorescence.
His studies deal with areas such as Depigmentation, Endocrinology, Incidence, Pigmentation disorder and Melanocyte as well as Vitiligo.
He most often published in these fields:
- Immunology (49.54%)
- Antibody (48.17%)
- Antigen (42.66%)
What were the highlights of his more recent work (between 2002-2017)?
- Immunology (49.54%)
- Dermatology (22.02%)
- Pemphigus (18.81%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Immunology, Dermatology, Pemphigus, Antibody and Pemphigus vulgaris.
His work in Immunology is not limited to one particular discipline; it also encompasses Melanoma.
The concepts of his Dermatology study are interwoven with issues in Severity of illness, Bullous pemphigoid and Disease.
His Pemphigus research integrates issues from Apoptosis, Retrospective cohort study and Immunopathology.
His biological study deals with issues like Ovalbumin, which deal with fields such as T cell.
His Pemphigus vulgaris research is multidisciplinary, relying on both Acantholysis, Desmoglein 3, Pathology, Desmoglein 1 and Prednisone.
Between 2002 and 2017, his most popular works were:
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus (340 citations)
- Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts (178 citations)
- Reliability and convergent validity of two outcome instruments for pemphigus. (135 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Immune system
His scientific interests lie mostly in Immunology, Dermatology, Disease, Pemphigus vulgaris and Pemphigus.
His Immunology study frequently involves adjacent topics like Melanoma.
In his study, Disease activity and Scoring system is inextricably linked to Severity of illness, which falls within the broad field of Dermatology.
He interconnects Clinical trial and Intensive care medicine in the investigation of issues within Disease.
His Pemphigus vulgaris study combines topics in areas such as Desmoglein 3, Acantholysis, Pathology, Desmoglein 1 and Desmoglein.
His Immunization study improves the overall literature in Antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
